Glioblastoma multiforme News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Late-stage study of Diffusion Pharma's TSC in brain cancer underway; shares up 4% after hours - Seeking Alpha



Nasdaq
 
Late-stage study of Diffusion Pharma's TSC in brain cancer underway; shares up 4% after hours 
Seeking Alpha
Diffusion Pharmaceuticals (NASDAQ:DFFN) is up 4% after hours on the heels of its announcement that the first patient has been dosed in a Phase 3 clinical trial, INTACT, assessing lead candidate trans sodium crocetinate (TSC) in patients with newly ...
Is Diffusion Pharmaceuticals Inc. (DFFN) a Sell? The Stock Reaches 52 Week Low Today BZ Weekly

all 10 news articles » 


Measuring the Magic of Healing - Scientific American (blog)



Scientific American (blog)
 
Measuring the Magic of Healing 
Scientific American (blog)
Three years into a brain cancer diagnosis that has an average survival rate of 18 months, Michael Bischoff of Minneapolis continues to heal. The 47-year-old husband and dad hopes for a cure, and for a long life. But with little control over the outcome ...

 


Global Recurrent Glioblastoma Multiforme Treatment Market Outlook 2018- Boehringer Ingelheim GmbH, Boston ... - Talk Daily News



Talk Daily News
 
Global Recurrent Glioblastoma Multiforme Treatment Market Outlook 2018- Boehringer Ingelheim GmbH, Boston ... 
Talk Daily News
Reportsbuzz added a new latest industry research report that focuses on ?Recurrent Glioblastoma Multiforme Treatment market ? and provides in-depth Global Recurrent Glioblastoma Multiforme Treatment market analysis and future prospects of Recurrent ...

 


Research project aims to find new ways to identify and treat most ... - News-Medical.net



News-Medical.net
 
Research project aims to find new ways to identify and treat most ... 
News-Medical.net
A large European research collaboration is bringing new technology to bear to combat two of the most aggressive brain cancers. The research project combines the expertise of leading biologists and electronic engineers to develop innovative ...

and more » 


Scientists target glioma cancer stem cells, which could improve patient survival - Science Daily



Scientists target glioma cancer stem cells, which could improve patient survival 
Science Daily
Glioblastoma multiforme is the most common and aggressive primary brain tumor and has one of the worst survival rates of all cancers. Despite surgery, radiation and chemotherapy, these tumors virtually always become resistant to therapy and eventually ...

and more » 


FDA Grants Humanitarian Use Designation for Nativis VoyagerŪ Pediatric System - Business Wire (press release)



Business Wire (press release)
 
FDA Grants Humanitarian Use Designation for Nativis VoyagerŪ Pediatric System 
Business Wire (press release)
... to a wide range of medical conditions as well as to veterinary medicine and non-medical applications. Nativis' initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies ...

and more » 


Undervalued And Attractive: Pick Up Novartis In 2018 - Seeking Alpha



Undervalued And Attractive: Pick Up Novartis In 2018 
Seeking Alpha
... research programs across multiple cancer indications. The company has already filed application with FDA to get Kymriah approved for adults suffering with relapsed or refractory diffuse large B-cell lymphoma. Novartis is also exploring potential of ...

and more » 


UI contributes to groundbreaking neurological research through NeuroNEXT network - Iowa Now



Iowa Now
 
UI contributes to groundbreaking neurological research through NeuroNEXT network 
Iowa Now
Others are testing existing drugs used to treat other diseases to see if they can be repurposed to treat neurological diseases. One such trial is to determine whether the drug Ibudilast, which has been prescribed for years in Japan to treat asthma, can ...

 


Recurrent Glioblastoma Multiforme Treatment Manufacturers Market Growth Prediction Up to 2025 - Ibnservice



Ibnservice
 
Recurrent Glioblastoma Multiforme Treatment Manufacturers Market Growth Prediction Up to 2025 
Ibnservice
Global Market Study Recurrent Glioblastoma Multiforme Treatment Market Provide Forecast Report 2018 ? 2025 presents an detailed analysis of the Recurrent Glioblastoma Multiforme Treatment which researched industry situations, market Size, growth and ...

 


DelMar Pharmaceuticals (DMPI) Shares Down 0% - The Ledger Gazette



DelMar Pharmaceuticals (DMPI) Shares Down 0% 
The Ledger Gazette
The legal version of this story can be viewed at https://ledgergazette.com/2018/02/21/delmar-pharmaceuticals-dmpi-shares-down-0.html. About DelMar Pharmaceuticals. DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company ...

and more »